An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis

Proteomics - Clinical Applications

Volumn 9, Issue 5-6, 2015, Pages 507-521

  Hepburn, Sophie ^a,b   Cairns, David A ^a   Jackson, David ^c   Craven, Rachel A ^a   Riley, Beverley ^a   Hutchinson, Michelle ^a   Wood, Steven ^a   Smith, Matthew Welberry ^a   Thompson, Douglas ^a,b   Banks, Rosamonde E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c Nonlinear Dynamics   (United Kingdom)

Author keywords

Peptides; Protease inhibitor; Proteomics; Temperature; Urine

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; PROTEINASE INHIBITOR; PROTEOME;

ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOASSAY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN PROCESSING; ROOM TEMPERATURE; SEPARATION TECHNIQUE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS; ADULT; AGED; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PROCEDURES; PROTEINURIA; PROTEOMICS; TEMPERATURE; URINE; URINE SAMPLING;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; PROTEOLYSIS; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TEMPERATURE; URINALYSIS; URINE SPECIMEN COLLECTION;

EID: 84930930229     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400079     Document Type: Article

References (40)

1. Decramer, S., de Peredo, A. G., Breuil, B., Mischak, H. et al., Urine in clinical proteomics. Mol. Cell. Proteomics 2008, 7, 1850-1862.
2. Thongboonkerd, V., Practical points in urinary proteomics. J. Proteome Res. 2007, 6, 3881-3890.
3. Konvalinka, A., Scholey, J. W., Diamandis, E. P., Searching for new biomarkers of renal diseases through proteomics. Clin. Chem. 2012, 58, 353-365.
4. Shariat, S. F., Karam, J. A., Raman, J. D., Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. Biomarkers Med. 2008, 2, 165-180.
5. Kentsis, A., Monigatti, F., Dorff, K., Campagne, F. et al., Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics Clin. Appl. 2009, 3, 1052-1061.
6. Coon, J. J., Zurbig, P., Dakna, M., Dominiczak, A. F. et al., CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin. Appl. 2008, 2, 964-973.
7. Siwy, J., Schanstra, J. P., Argiles, A., Bakker, S. J. et al., Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol. Dial. Transplant 2014, 29, 1563-1570.
8. Court, M., Selevsek, N., Matondo, M., Allory, Y. et al., Toward a standardized urine proteome analysis methodology. Proteomics 2011, 11, 1160-1171.
9. Afkarian, M., Bhasin, M., Dillon, S. T., Guerrero, M. C. et al., Optimizing a proteomics platform for urine biomarker discovery. Mol. Cell. Proteomics 2010, 9, 2195-2204.
10. Good, D. M., Zurbig, P., Argiles, A., Bauer, H. W. et al., Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteomics 2010, 9, 2424-2437.
11. Calvano, C. D., Aresta, A., Iacovone, M., De Benedetto, G. E. et al., Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles. J. Pharm. Biomed. Anal. 2010, 51, 907-914.
12. Havanapan, P.-O., Thongboonkerd, V., Are protease inhibitors required for gel-based proteomics of kidney and urine? J. Proteome Res. 2009, 8, 3109-3117.
13. Jackson, D. H., Banks, R. E., Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clin. Appl. 2010, 4, 250-270.
14. Moore, H. M., Kelly, A. B., Jewell, S. D., McShane, L. M. et al., Biospecimen reporting for improved study quality (BRISQ). J. Proteome Res. 2011, 10, 3429-3438.
15. Thomas, C. E., Sexton, W., Benson, K., Sutphen, R., Koomen, J., Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 953-959.
16. Lee, R. S., Monigatti, F., Briscoe, A. C., Waldon, Z. et al., Optimizing sample handling for urinary proteomics. J. Proteome Res. 2008, 7, 4022-4030.
17. Waikar, S. S., Betensky, R. A., Bonventre, J. V., Creatinine as the gold standard for kidney injury biomarker studies? Nephrol. Dial. Transpl. 2009, 24, 3263-3265.
18. Petri, A. L., Hogdall, C., Christensen, I. J., Simonsen, A. H. et al., Sample handling for mass spectrometric proteomic investigations of human urine. Proteomics Clin. Appl. 2008, 2, 1184-1193.
19. Papale, M., Pedicillo, M. C., Thatcher, B. J., Di Paolo, S. et al., Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis. J. Chromatog. B 2007, 856, 205-213.
20. Banks, R. E., Stanley, A. J., Cairns, D. A., Barrett, J. H. et al., Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 2005, 51, 1637-1649.
21. Thompson, D., Develter, W., Cairns, D. A., Barrett, J. H. et al., A pilot study to investigate the potential of mass spectrometry profiling in the discovery of novel serum markers in chronic renal disease. Proteomics Clin. Appl. 2011, 5, 523-531.
22. Welberry Smith, M. P., Wood, S. L., Zougman, A., Ho, J. T. et al., A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics 2011, 11, 2222-2235.
23. Bates, D., Maechler, M., Bolker, B., Walker, S., Ime4: linear mixed-effects models using Eigen and S4.R package version 1.1-5.
24. Nagaraj, N., Mann, M., Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. J. Proteome Res. 2011, 10, 637-645.
25. Zhou, H., Yuen, P. S. T., Pisitkun, T., Gonzales, P. A. et al., Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int. 2006, 69, 1471-1476.
26. Parikh, C. R., Butrymowicz, I., Yu, A., Chinchilli, V. M. et al., Urine stability studies for novel biomarkers of acute kidney injury. Am. J. Kidney Dis. 2014, 63, 567-572.
27. Schultz, C. J., Dalton, R. N., Turnert, C., Neil, H. A. W., Dunger, D. B., Freezing method affects the concentration and variability of urine proteins and the interpretation of data on microalbuminuria. Diabet. Med. 2000, 17, 7-14.
28. Kania, K., Byrnes, E. A., Beilby, J. P., Webb, S. A., Strong, K. J., Urinary proteases degrade albumin: implications for measurement of albuminuria in stored samples. Ann. Clin. Biochem. 2010, 47, 151-157.
29. Filip, S., Pontillo, C., Peter Schanstra, J., Vlahou, A. et al., Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. Expert Rev. Proteomics 2014, 1-14.
30. Schuchard, M. D., Mehigh, R. J., Cockrill, S. L., Lipscomb, G. T. et al., Artifactual isoform profile modification following treatment of human plasma or serum with protease inhibitor, monitored by 2-dimensional electrophoresis and mass spectrometry. BioTechniques 2005, 39, 239-247.
31. Mischak, H., Vlahou, A., Ioannidis, J. P., Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin. Biochem. 2013, 46, 432-443.
32. Theodorescu, D., Wittke, S., Ross, M. M., Walden, M. et al., Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006, 7, 230-240.
33. Fiedler, G. M., Baumann, S., Leichtle, A., Oltmann, A. et al., Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2007, 53, 421-428.
34. Schaub, S., Wilkins, J., Weiler, T., Sangster, K. et al., Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 2004, 65, 323-332.
35. Townsend, J. C., Sadler, W. A., Shanks, G. M., The effect of storage pH on the precipitation of proteins in deep frozen urine samples. Ann. Clin. Biochem. 1987, 24, 111-112.
36. Hatipoglu, S., Sevketoglu, E., Gedikbasi, A., Yilmaz, A. et al., Urinary MMP-9/NGAL complex in children with acute cystitis. Pediatr. Nephrol. 2011, 26, 1263-1268.
37. Wong, W., DeVito, J., Nguyen, H., Sarracino, D. et al., Chronic humoral rejection of human kidney allografts is associated with MMP-2 accumulation in podocytes and its release in the urine. Am. J. Transplant. 2010, 10, 2463-2471.
38. Metzger, J., Chatzikyrkou, C., Broecker, V., Schiffer, E. et al., Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin. Appl. 2011, 5, 322-333.
39. Caseiro, A., Ferreira, R., Quintaneiro, C., Pereira, A. et al., Protease profiling of different biofluids in type 1 diabetes mellitus. Clin. Biochem. 2012, 45, 1613-1619.
40. Hirt-Minkowski, P., Marti, H. P., Honger, G., Grandgirard, D. et al., Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation. Transplant. Immunol. 2014, 30, 1-6.